Phenibut (beta-Phenyl-GABA)

GABAergicoral · inferred

Synthetic GABA-B receptor agonist with some GABA-A activity, originally developed in Russia for cosmonauts. Crosses blood-brain barrier unlike GABA itself due to phenyl group. Largely excreted unchanged (~63% in urine). HIGH ADDICTION POTENTIAL with severe withdrawal syndrome (seizures, psychosis, delirium). Not FDA-approved. Do NOT use daily or combine with other depressants.

Projected serum levels — 500 mg, once daily

Phenibut (beta-Phenyl-GABA)
Phenibut (beta-Phenyl-GABA) modeled serum levels, 500 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 62.5 125 188 250 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 500 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 203 mg, trough ≈ 1.4 mg body load. Population-based estimate over 15 days for a 500 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
GABAergic
Route modeled
Oral
Model confidence
inferred
Half-life
5.3 h
Common dose
500 mg
Suggested maximum
1.5k mg/day
Reference dose range
250–1.5k mg (single dose)
Suggested cadence
once daily

Documented interactions

  • danger
    1,4-BDO (1,4-Butanediol) + Phenibut (beta-Phenyl-GABA) Contraindicated

    1,4-BDO converts to GHB. Phenibut is also a GABA-B agonist with a very long half-life (~5h); combined GABA-B agonism produces severe respiratory depression and prolonged unconsciousness.

  • danger
    Ethanol (Alcohol) + Phenibut (beta-Phenyl-GABA) Contraindicated

    Phenibut and alcohol are both CNS depressants acting on GABA receptors. Combined use dramatically increases risk of respiratory depression, loss of consciousness, and death.

  • danger
    Gabapentin (Neurontin) + Phenibut (beta-Phenyl-GABA) Contraindicated

    Phenibut and gabapentin both modulate GABAergic signalling. Combined use potentiates CNS depression, causing excessive sedation, respiratory depression, and increased addiction risk.

  • danger
    GHB (Gamma-Hydroxybutyrate) + Phenibut (beta-Phenyl-GABA) Contraindicated

    Both phenibut and GHB are potent GABA-B agonists. Combined use causes severe respiratory depression with high risk of coma and death.

  • moderate
    GABA (Gamma-Aminobutyric Acid) + Phenibut (beta-Phenyl-GABA) Stacked effects

    GABA (Gamma-Aminobutyric Acid) and Phenibut (beta-Phenyl-GABA) both push the gaba a and gaba b in the same direction.

  • watch
    Baclofen (Lioresal) + Phenibut (beta-Phenyl-GABA) Stacked effects

    Baclofen (Lioresal) and Phenibut (beta-Phenyl-GABA) both push the gaba b in the same direction.

Serum checks 15 modeled interaction pairings for phenibut (beta-phenyl-gaba) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug Lapin IP · CNS Drug Reviews, 2001 DOI

    Foundational review establishing phenibut as a GABA-mimetic acting primarily at GABA-B and partly at GABA-A receptors, with dopamine-stimulating and PEA-antagonist properties mediating its anxiolytic and nootropic…

  2. Phenibut (beta-phenyl-gamma-aminobutyric acid) dependence and management of withdrawal: emerging nootropics of abuse Ahuja T et al. · Case Reports in Psychiatry, 2018 DOI

    Case report documenting severe phenibut withdrawal (psychomotor agitation, hallucinations, psychosis) requiring ICU admission and baclofen taper, establishing phenibut as an emerging substance of dependence.

  3. Phenibut: a drug with one too many "buts" Gurley BJ · Basic & Clinical Pharmacology & Toxicology, 2024 DOI

    Comprehensive pharmacological review confirming phenibut activity at GABA-B, GABA-A, and beta-PEA receptors, detailing its pharmacokinetics (5.3h half-life, 63% renal excretion unchanged), and documenting escalating…

3 published studies referenced in the app, each with a plain-language summary.